Women's Sexual Health Company Changes Name in Preparation for Market Entry

TivaMed Becomes Viveve

PALO ALTO, Calif., Nov. 9 /PRNewswire/ -- Women's sexual health company,
TivaMed, today announced it has changed its name to Viveve as it prepares for
a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

"Viveve is a name that we believe captures the essence of our company focus on
women's sexual health," said Kerry Pope, Viveve's president and chief
executive. "Viveve exists for the sole purpose of helping women restore their
sense of fulfillment and sexual satisfaction to the level that they enjoyed
prior to giving birth."

The company has developed the Viveve procedure, a quick and painless
nonsurgical treatment for women who have experienced vaginal looseness and
loss of physical sensation that is common to many women after vaginal
childbirth. The Viveve procedure uses radiofrequency energy to stimulate the
body's natural collagen rebuilding process at the vaginal opening. Viveve has
been shown in a clinical study to increase a woman's feeling of vaginal
tightness and improve her sexual satisfaction during vaginal intercourse.

Research has shown that many women experience a feeling of looseness and a
loss of physical sensation following vaginal childbirth; however, the
condition is vastly underreported according to a recent study of more than 500
practicing OB/GYNs(1),(2)

"The problem is two-fold. Most women are uncomfortable speaking with their
physicians about vaginal laxity and many physicians feel awkward bringing up
this subject in fear of offending women. Many are not fully aware of
treatment options that are available," said Sandra Carson, MD, chief of
Reproductive Endocrinology at women and Infants Hospital at Brown University.
"I expect the Viveve procedure will provide a catalyst for a conversation
between patients and their physicians about vaginal laxity."

The Viveve system received FDA clearance in 2008. Three-month follow up
results from Viveve's first-in-women trial will be presented later this month
at the AAGL annual meeting, November 15 - 19 in Orlando, Florida.

The company's Series A financing was led by GBS Venture Partners and 5AM
Ventures. For more information, visit the Viveve Web site at www.viveve.com or
phone 650-321-3332.

About 5AM Ventures:
Founded in 2002, 5AM Ventures makes seed and early-stage investments in
next-generation life science companies, taking a focused, hands-on approach to
company building. The 5AM portfolio is diversified among innovative
platforms, spinouts from established biotechnology and pharmaceutical
companies, and companies developing near-term products. For more information
about 5AM Ventures, please visit www.5amventures.com.

About GBS Ventures:
GBS Venture Partners (GBS) is a leading life science venture capital firm
founded in 1996. GBS invests in young businesses developing and
commercializing products which, when combined with the right management and
finance, will make a significant difference to patients' lives and deliver
financial returns for our investors. For more information about GBS, please
visit www.gbsventures.com.au.

(1) Barrett G. et al, Women's Sexual Health after Childbirth, British Journal
of Obstetrics and Gynaecology, 2000, 107 (2) PP 186-195
(2) Data on file. OB/GYN Alliance, sponsored by Viveve. October 2009

SOURCE Viveve

Sherree Lucas, Viveve, +1-650-321-3332 Ext 213, slucas@viveve.com; or Angela
Gillespie of WeissComm Group, +1-415-946-1091, or +1-415-312-2504,
agillespie@wcpglobal.com